Table 1

Summary of intake data by receptor status and antioestrogenic drug prescription
Total phytoestrogen intake (μg/1,000 kcal) (n = 316)
 n
 First quartile
 Second quartile
 Third quartile
 Fourth quartile


Receptor status




Mean
 8,388
      ER-negative
 42
 11 (14%)
 11 (14%)
 13 (16%)
 7 (9%)
Range
 126 to 77,703
      ER-positive
 182
 40 (51%)
 42 (53%)
 48 (61%)
 52 (66%)
Quartile ranges
     Not available
 92
 28 (35%)
 26 (33%)
 18 (23%)
 20 (25%)
     First quartile
 <3,817
 Antioestrogenic drugs




     Second quartile
 3,817 to 6,798
      No prescription
 109
 30 (38%)
 30 (38%)
 25(32%)
 24 (30%)
     Third quartile
 6,799 to 10,255
      Tamoxifen or arimidexa
 200
 47 (59%)
 47 (59%)
 52 (65%)
 54 (68%)
     Fourth quartile
 >10,255
      Other/missing
 7
 2 (3%)
 2 (3%)
 2 (3%)
 1 (2%)

aAstraZeneca, London, UK.

Parry et al. Breast Cancer Research 2008 10(Suppl 2):P92   doi:10.1186/bcr1976